EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure

Jolieke A T van Osch, Jolanda J C Voermans, Haajar Ouzerne, Alicia B H Cromme, Ehikioya Azugbene, Mike Voskamp, Zoë Krullaars, Rizwan Mahmud, Ronald J Overmars, Alicja U Gorska, Cynthia Lungu iD, David A M C van De Vijver und 3 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Jolieke A T van Osch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Viroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV-1, HIV Integrase, HIV Infections. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderek, Dutch Aidsfonds, Aidsfonds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Mutations in the 3′-polypurine tract (3′PPT) of HIV-1 have been observed under pressure with two integrase strand transfer inhibitors, dolutegravir and cabotegravir. In the DOMONO randomized clinical trial, 3′PPT mutations emerged in a participant who experienced treatment failure under dolutegravir monotherapy. To understand the basis for this rare mutational pathway, we examined baseline viral sequences and identified the K156N natural polymorphism. Given the role of K156 in viral DNA binding, the potential relationship between K156N and 3′PPT mutations was further investigated.

Methods

We assessed the impact of K156N on integrase using in silico modelling and biochemical assays with recombinant proteins. Infectivity, replicative capacity, and drug susceptibility of viruses carrying K156N, 3′PPT mutations, or both were measured. Viral evolution was assessed in cell culture.

Results

Structural models indicated that K156N altered viral DNA binding. K156N reduced strand transfer activity through decreased affinity for the LTR but increased 3′-processing. The K156N virus had normal infectivity, whereas the 3′PPT mutations decreased infectiousness sixfold and lowered maximal infectivity. K156N partially compensated for this defect, but maximal infectivity remained diminished. K156N also partially compensated for defects in replicative capacity imposed by 3′PPT mutations. K156N alone did not confer resistance against dolutegravir, nor did it increase the modest (2.5-fold) resistance conferred by the 3′PPT mutations. K156N alone promoted the spontaneous emergence of 3′PPT mutations distinct from those seen in DOMONO.

Conclusions

These findings establish a direct functional relationship between natural variation in HIV-1 integrase and the emergence of 3′PPT mutations. People harbouring a virus with the K156N natural polymorphism may be predisposed to developing 3′PPT mutations upon failure with DTG. However, the clinical relevance of this association remains to be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingHIV-1HIV IntegraseHIV InfectionsHIV Integrase InhibitorsPolymorphism, GeneticMutation, MissenseOxazinesPiperazinesDolutegravirHumansTreatment FailurePyridonesDrug Resistance, ViralModels, MolecularMutationVirus Replication

Substanzen

OxazinesPiperazinesDolutegravirHeterocyclic Compounds, 3-RingHIV IntegrasePyridonesp31 integrase protein, Human immunodeficiency virus 1HIV Integrase Inhibitors

Autor:innen und Institutionen

  • Viroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Cynthia Lungu, Thibault Mesplède

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderek
  • Dutch Aidsfonds
  • Aidsfonds
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • Canadian Institutes for Health Research
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

van Osch, J. A. T., Voermans, J. J. C., Ouzerne, H., Cromme, A. B. H., Azugbene, E., Voskamp, M., Krullaars, Z., Mahmud, R., Overmars, R. J., Gorska, A. U., Lungu, C., van De Vijver, D. A. M. C., Gruters, R. A., van Kampen, J. J. A., & Mesplède, T. (2026). Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag033

Vancouver

van Osch JAT, Voermans JJC, Ouzerne H, Cromme ABH, Azugbene E, Voskamp M, et al. Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag033

BibTeX
@article{vanOsch2026,
  author = {van Osch, Jolieke A T and Voermans, Jolanda J C and Ouzerne, Haajar and Cromme, Alicia B H and Azugbene, Ehikioya and Voskamp, Mike and Krullaars, Zoë and Mahmud, Rizwan and Overmars, Ronald J and Gorska, Alicja U and Lungu, Cynthia and van De Vijver, David A M C and Gruters, Rob A and van Kampen, Jeroen J A and Mesplède, Thibault},
  title = {Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag033}
}
Kostenlos starten →